BEAM Beam Therapeutics

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 11:00 a.m. ET in New York.

The live webcast will be available in the investor section of the company's website at and will be archived for 60 days following the presentation.

About Beam Therapeutics

Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contact:

Holly Manning

Beam Therapeutics



EN
13/05/2025

Underlying

BEAMBeam Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Beam Therapeutics

 PRESS RELEASE
Free
BEAM Beam Therapeuti...

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted t...

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD). “Sickle cell disease is a devasting disorder that affects approximately 100,000 people ...

7h / 42m 1 EN
 PRESS RELEASE
Free
BEAM Beam Therapeuti...

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted t...

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with a...

May 29, 2025 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
BEAM BEAM THERAPEUTICS
GMTX GEMINI THERAPEUTICS INC
ARTV ARTIVA BIOTHERAPEUTICS INC
05/14/25 May 14, 2025 1 EN
 PRESS RELEASE
Free
BEAM Beam Therapeuti...

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickl...

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101 Beam to Host Investor Webcast on Friday, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present new data from ...

May 14, 2025 1 EN
 PRESS RELEASE
Free
BEAM Beam Therapeuti...

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global He...

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 11:00 a.m. ET in New York. The live webcast will be available in the investor section of the company's website at and will be archived for 60 days following the presentation. About Beam Thera...

May 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch